Newly Diagnosed Multiple Myeloma Clinical Trials

5 recruiting

Frequently Asked Questions

Common questions about Newly Diagnosed Multiple Myeloma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

18F-Fluciclovine PET/CT in Multiple Myeloma

Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI)60 enrolled1 locationNCT06103838
Recruiting
Phase 3

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

Multiple MyelomaNewly Diagnosed Multiple Myeloma
GlaxoSmithKline520 enrolled174 locationsNCT06679101
Recruiting

Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients

Newly Diagnosed Multiple Myeloma (NDMM)
Peking University People's Hospital500 enrolled1 locationNCT07296627
Recruiting

Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Diagnosed Multiple Myeloma Patients

Newly Diagnosed Multiple Myeloma (NDMM)
Universiteit Antwerpen120 enrolled4 locationsNCT07087964
Recruiting
Not Applicable

Biomarkers in Multiple Myeloma

ChemotherapyNewly Diagnosed Multiple MyelomaHematological Patients
Centre Hospitalier Universitaire de Saint Etienne70 enrolled2 locationsNCT05259553
Recruiting
Phase 2Phase 3

Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

Newly Diagnosed Multiple Myeloma
University Hopsital Schleswig Holstein Campus Lübeck100 enrolled6 locationsNCT05665140
Recruiting

Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients

Newly Diagnosed Multiple Myeloma
The First Affiliated Hospital of Soochow University50 enrolled1 locationNCT06682156
Recruiting
Phase 2Phase 3

Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation

Newly Diagnosed Multiple Myeloma
Jinling Hospital, China80 enrolled1 locationNCT06324266